GeoVax Labs, Inc. (NASDAQ:GOVX) Sees Large Increase in Short Interest

GeoVax Labs, Inc. (NASDAQ:GOVX) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 836,900 shares, an increase of 13.5% from the October 15th total of 737,500 shares. Based on an average trading volume of 267,200 shares, the days-to-cover ratio is currently 3.1 days.

Hedge Funds Weigh In On GeoVax Labs

A number of large investors have recently made changes to their positions in GOVX. Millennium Management LLC purchased a new position in GeoVax Labs during the second quarter valued at approximately $27,000. Virtu Financial LLC boosted its stake in shares of GeoVax Labs by 39.1% during the 2nd quarter. Virtu Financial LLC now owns 69,093 shares of the company’s stock valued at $57,000 after buying an additional 19,409 shares during the period. Geode Capital Management LLC grew its holdings in shares of GeoVax Labs by 18.1% during the 4th quarter. Geode Capital Management LLC now owns 172,750 shares of the company’s stock valued at $108,000 after acquiring an additional 26,462 shares in the last quarter. State Street Corp increased its stake in shares of GeoVax Labs by 659.4% in the third quarter. State Street Corp now owns 168,142 shares of the company’s stock worth $183,000 after acquiring an additional 146,000 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of GeoVax Labs during the second quarter worth $333,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of GeoVax Labs in a research report on Monday.

GeoVax Labs Stock Performance

Shares of GeoVax Labs stock opened at $0.54 on Friday. GeoVax Labs has a 1 year low of $0.47 and a 1 year high of $1.39. The company has a market cap of $14.53 million, a P/E ratio of -0.61 and a beta of 2.93. The stock has a 50-day moving average price of $0.53 and a 200 day moving average price of $0.57.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.